Search

Item does not contain fulltext

Item does not contain fulltext

Contains fulltext : 295363.pdf (Publisher’s version ) (Open Access)

Contains fulltext : 241945.pdf (Author’s version preprint ) (Open Access)

Contains fulltext : 238671.pdf (Publisher’s version ) (Open Access)

Item does not contain fulltext

Contains fulltext : 240392.pdf (Publisher’s version ) (Open Access)

Item does not contain fulltext

Contains fulltext : 238671.pdf (Publisher’s version ) (Open Access)

Contains fulltext : 241945.pdf (Author’s version preprint ) (Open Access)

Contains fulltext : 240392.pdf (Publisher’s version ) (Open Access)

Contains fulltext : 238671.pdf (Publisher’s version ) (Open Access)

Item does not contain fulltext

Contains fulltext : 225457.pdf (Publisher’s version ) (Closed access), AIMS: To evaluate long-term safety and efficacy of ticagrelor monotherapy in patients undergoing percutaneous coronary interventions (PCIs) in relation to chronic obstructive pulmonary disease (COPD) at baseline and the occurrence of dyspnoea reported as adverse event (AE) that may lead to treatment non-adherence. METHODS AND RESULTS: This is a non-prespecified, post hoc analysis of the randomized GLOBAL LEADERS trial (n = 15 991), comparing the experimental strategy of 23-month ticagrelor monotherapy following 1-month dual antiplatelet therapy (DAPT) after PCI with the reference strategy of 12-month DAPT followed by 12-month aspirin monotherapy. Impact of COPD and dyspnoea AE (as a time-dependent covariate) on clinical outcomes was evaluated up to 2 years. The primary endpoint was a 2-year all-cause mortality or non-fatal, centrally adjudicated, new Q-wave myocardial infarction. The presence of COPD (n = 832) was the strongest clinical predictor of 2-year all-cause mortality after PCI [hazard ratio (HR) 2.84; 95% confidence interval (CI) 2.21-3.66; P adjusted = 0.001] in this cohort (n = 15 991). No differential treatment effects on 2-year clinical outcomes were found in patients with and without COPD (primary endpoint: HR 0.88; 95% CI 0.58-1.35; P = 0.562; P int = 0.952). Overall, at 2 years dyspnoea was reported as an AE in 2101 patients, more frequently among COPD patients, irrespective of treatment allocation (27.2% in experimental arm vs. 14.5% in reference arm, P = 0.001). Its occurrence was not associated with a higher rate of the primary endpoint (P adjusted = 0.640) in the experimental vs. the reference arm. CONCLUSION: In this exploratory analysis, COPD negatively impacted long-term prognosis after PCI. Despite higher incidence of dyspnoea in the experimental arm, in particular among COPD patients, the safety of the experimental treatment strategy appeared not to be affected. CLINICAL TRIAL REGISTRATION UNIQUE IDENTIFIER: NCT01813435.

Contains fulltext : 214716pub.pdf (publisher's version ) (Open Access)

Contains fulltext : 228109.pdf (publisher's version ) (Open Access)

Contains fulltext : 225457.pdf (Publisher’s version ) (Closed access), AIMS: To evaluate long-term safety and efficacy of ticagrelor monotherapy in patients undergoing percutaneous coronary interventions (PCIs) in relation to chronic obstructive pulmonary disease (COPD) at baseline and the occurrence of dyspnoea reported as adverse event (AE) that may lead to treatment non-adherence. METHODS AND RESULTS: This is a non-prespecified, post hoc analysis of the randomized GLOBAL LEADERS trial (n = 15 991), comparing the experimental strategy of 23-month ticagrelor monotherapy following 1-month dual antiplatelet therapy (DAPT) after PCI with the reference strategy of 12-month DAPT followed by 12-month aspirin monotherapy. Impact of COPD and dyspnoea AE (as a time-dependent covariate) on clinical outcomes was evaluated up to 2 years. The primary endpoint was a 2-year all-cause mortality or non-fatal, centrally adjudicated, new Q-wave myocardial infarction. The presence of COPD (n = 832) was the strongest clinical predictor of 2-year all-cause mortality after PCI [hazard ratio (HR) 2.84; 95% confidence interval (CI) 2.21-3.66; P adjusted = 0.001] in this cohort (n = 15 991). No differential treatment effects on 2-year clinical outcomes were found in patients with and without COPD (primary endpoint: HR 0.88; 95% CI 0.58-1.35; P = 0.562; P int = 0.952). Overall, at 2 years dyspnoea was reported as an AE in 2101 patients, more frequently among COPD patients, irrespective of treatment allocation (27.2% in experimental arm vs. 14.5% in reference arm, P = 0.001). Its occurrence was not associated with a higher rate of the primary endpoint (P adjusted = 0.640) in the experimental vs. the reference arm. CONCLUSION: In this exploratory analysis, COPD negatively impacted long-term prognosis after PCI. Despite higher incidence of dyspnoea in the experimental arm, in particular among COPD patients, the safety of the experimental treatment strategy appeared not to be affected. CLINICAL TRIAL REGISTRATION UNIQUE IDENTIFIER: NCT01813435.

Contains fulltext : 214716pub.pdf (Publisher’s version ) (Closed access)

Contains fulltext : 228109.pdf (publisher's version ) (Open Access)

Contains fulltext : 214716pub.pdf (Publisher’s version ) (Closed access)

Contains fulltext : 228109.pdf (publisher's version ) (Open Access)

Contains fulltext : 225457.pdf (Publisher’s version ) (Closed access), AIMS: To evaluate long-term safety and efficacy of ticagrelor monotherapy in patients undergoing percutaneous coronary interventions (PCIs) in relation to chronic obstructive pulmonary disease (COPD) at baseline and the occurrence of dyspnoea reported as adverse event (AE) that may lead to treatment non-adherence. METHODS AND RESULTS: This is a non-prespecified, post hoc analysis of the randomized GLOBAL LEADERS trial (n = 15 991), comparing the experimental strategy of 23-month ticagrelor monotherapy following 1-month dual antiplatelet therapy (DAPT) after PCI with the reference strategy of 12-month DAPT followed by 12-month aspirin monotherapy. Impact of COPD and dyspnoea AE (as a time-dependent covariate) on clinical outcomes was evaluated up to 2 years. The primary endpoint was a 2-year all-cause mortality or non-fatal, centrally adjudicated, new Q-wave myocardial infarction. The presence of COPD (n = 832) was the strongest clinical predictor of 2-year all-cause mortality after PCI [hazard ratio (HR) 2.84; 95% confidence interval (CI) 2.21-3.66; P adjusted = 0.001] in this cohort (n = 15 991). No differential treatment effects on 2-year clinical outcomes were found in patients with and without COPD (primary endpoint: HR 0.88; 95% CI 0.58-1.35; P = 0.562; P int = 0.952). Overall, at 2 years dyspnoea was reported as an AE in 2101 patients, more frequently among COPD patients, irrespective of treatment allocation (27.2% in experimental arm vs. 14.5% in reference arm, P = 0.001). Its occurrence was not associated with a higher rate of the primary endpoint (P adjusted = 0.640) in the experimental vs. the reference arm. CONCLUSION: In this exploratory analysis, COPD negatively impacted long-term prognosis after PCI. Despite higher incidence of dyspnoea in the experimental arm, in particular among COPD patients, the safety of the experimental treatment strategy appeared not to be affected. CLINICAL TRIAL REGISTRATION UNIQUE IDENTIFIER: NCT01813435.

Item does not contain fulltext, AIMS: The aim of this study was to evaluate the impact of 23-month ticagrelor monotherapy following one-month dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI) on the rates of patient-oriented composite endpoints (POCE) and net adverse clinical events (NACE). METHODS AND RESULTS: The rates of site-reported Academic Research Consortium (ARC)-2 defined POCE (all-cause death, any stroke, any myocardial infarction or any revascularisation) and NACE (POCE or bleeding type 3 or 5 according to the Bleeding ARC [BARC]) were reported up to two years by intention-to-treat principle in the randomised, multicentre, open-label GLOBAL LEADERS study comparing two antiplatelet strategies in 15,991 patients undergoing PCI. The experimental strategy consisted of aspirin with ticagrelor for one month followed by ticagrelor monotherapy for 23 months, whereas the reference treatment consisted of 12-month DAPT followed by 12-month aspirin monotherapy. At two years, POCE occurred in 1,050 (13.2%) patients in the experimental group and in 1,131 (14.2%) in the reference group (HR 0.93, 95% CI: 0.85-1.01, p=0.085). NACE occurred in 1,145 (14.4%) patients in the experimental group and in 1,237 (15.5%) patients in the reference group (HR 0.92, 95% CI: 0.85-1.00, p=0.057). In pre-specified subgroup analyses, no significant treatment-by-subgroup interactions were found for either POCE or NACE at two years. CONCLUSIONS: The experimental treatment strategy of one-month DAPT followed by 23 months of ticagrelor alone did not result in a significant reduction in the rates of site-reported POCE or NACE, when compared to the reference treatment. ClinicalTrials.gov Identifier: NCT01813435.

Item does not contain fulltext, Transnational private regulation has been woven into the fabric of modern food safety governance. In this paper we explore the question of how domestic state actors respond to this development. We address this question in a detailed case study about the Global Food Safety Initiative (GFSI) and domestic food safety authorities in Canada, China, and the Netherlands. Why and to what extent do these domestic actors engage with GFSI in their regulatory activities, and what are the effects? To develop a better understanding of the how and why of this interaction, the paper builds on the concept of ‘regulatory enrolment’ developed by Black (2003). As will be argued, enrolment offers a proper analytical lens through which the nature of interplay between various actors in a regulatory regime can be better appreciated and the capacity of that regime as a whole can be enhanced in smart and innovative ways.

Contains fulltext : 201463pub.pdf (publisher's version ) (Open Access)

Contains fulltext : 202729pos.pdf (postprint version ) (Open Access)

Contains fulltext : 209816.pdf (publisher's version ) (Open Access)

Liber amicorum in honour of prof. dr. Elspeth Guild, Contains fulltext : 207699pub.pdf (publisher's version ) (Open Access)

Contains fulltext : 209320.pdf (publisher's version ) (Open Access)

Item does not contain fulltext, AIMS: The aim of this study was to evaluate the impact of 23-month ticagrelor monotherapy following one-month dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI) on the rates of patient-oriented composite endpoints (POCE) and net adverse clinical events (NACE). METHODS AND RESULTS: The rates of site-reported Academic Research Consortium (ARC)-2 defined POCE (all-cause death, any stroke, any myocardial infarction or any revascularisation) and NACE (POCE or bleeding type 3 or 5 according to the Bleeding ARC [BARC]) were reported up to two years by intention-to-treat principle in the randomised, multicentre, open-label GLOBAL LEADERS study comparing two antiplatelet strategies in 15,991 patients undergoing PCI. The experimental strategy consisted of aspirin with ticagrelor for one month followed by ticagrelor monotherapy for 23 months, whereas the reference treatment consisted of 12-month DAPT followed by 12-month aspirin monotherapy. At two years, POCE occurred in 1,050 (13.2%) patients in the experimental group and in 1,131 (14.2%) in the reference group (HR 0.93, 95% CI: 0.85-1.01, p=0.085). NACE occurred in 1,145 (14.4%) patients in the experimental group and in 1,237 (15.5%) patients in the reference group (HR 0.92, 95% CI: 0.85-1.00, p=0.057). In pre-specified subgroup analyses, no significant treatment-by-subgroup interactions were found for either POCE or NACE at two years. CONCLUSIONS: The experimental treatment strategy of one-month DAPT followed by 23 months of ticagrelor alone did not result in a significant reduction in the rates of site-reported POCE or NACE, when compared to the reference treatment. ClinicalTrials.gov Identifier: NCT01813435.

Item does not contain fulltext, Transnational private regulation has been woven into the fabric of modern food safety governance. In this paper we explore the question of how domestic state actors respond to this development. We address this question in a detailed case study about the Global Food Safety Initiative (GFSI) and domestic food safety authorities in Canada, China, and the Netherlands. Why and to what extent do these domestic actors engage with GFSI in their regulatory activities, and what are the effects? To develop a better understanding of the how and why of this interaction, the paper builds on the concept of ‘regulatory enrolment’ developed by Black (2003). As will be argued, enrolment offers a proper analytical lens through which the nature of interplay between various actors in a regulatory regime can be better appreciated and the capacity of that regime as a whole can be enhanced in smart and innovative ways.

Contains fulltext : 201463pub.pdf (publisher's version ) (Open Access)

Contains fulltext : 202729pos.pdf (postprint version ) (Open Access)

Contains fulltext : 209816.pdf (publisher's version ) (Open Access)

Contains fulltext : 209320.pdf (publisher's version ) (Open Access)

Liber amicorum in honour of prof. dr. Elspeth Guild, Contains fulltext : 207699pub.pdf (publisher's version ) (Open Access)

Liber amicorum in honour of prof. dr. Elspeth Guild, Contains fulltext : 207699pub.pdf (publisher's version ) (Open Access)

Contains fulltext : 201463pub.pdf (publisher's version ) (Open Access)

Contains fulltext : 209816.pdf (publisher's version ) (Open Access)

Item does not contain fulltext, AIMS: The aim of this study was to evaluate the impact of 23-month ticagrelor monotherapy following one-month dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI) on the rates of patient-oriented composite endpoints (POCE) and net adverse clinical events (NACE). METHODS AND RESULTS: The rates of site-reported Academic Research Consortium (ARC)-2 defined POCE (all-cause death, any stroke, any myocardial infarction or any revascularisation) and NACE (POCE or bleeding type 3 or 5 according to the Bleeding ARC [BARC]) were reported up to two years by intention-to-treat principle in the randomised, multicentre, open-label GLOBAL LEADERS study comparing two antiplatelet strategies in 15,991 patients undergoing PCI. The experimental strategy consisted of aspirin with ticagrelor for one month followed by ticagrelor monotherapy for 23 months, whereas the reference treatment consisted of 12-month DAPT followed by 12-month aspirin monotherapy. At two years, POCE occurred in 1,050 (13.2%) patients in the experimental group and in 1,131 (14.2%) in the reference group (HR 0.93, 95% CI: 0.85-1.01, p=0.085). NACE occurred in 1,145 (14.4%) patients in the experimental group and in 1,237 (15.5%) patients in the reference group (HR 0.92, 95% CI: 0.85-1.00, p=0.057). In pre-specified subgroup analyses, no significant treatment-by-subgroup interactions were found for either POCE or NACE at two years. CONCLUSIONS: The experimental treatment strategy of one-month DAPT followed by 23 months of ticagrelor alone did not result in a significant reduction in the rates of site-reported POCE or NACE, when compared to the reference treatment. ClinicalTrials.gov Identifier: NCT01813435.

Item does not contain fulltext, Transnational private regulation has been woven into the fabric of modern food safety governance. In this paper we explore the question of how domestic state actors respond to this development. We address this question in a detailed case study about the Global Food Safety Initiative (GFSI) and domestic food safety authorities in Canada, China, and the Netherlands. Why and to what extent do these domestic actors engage with GFSI in their regulatory activities, and what are the effects? To develop a better understanding of the how and why of this interaction, the paper builds on the concept of ‘regulatory enrolment’ developed by Black (2003). As will be argued, enrolment offers a proper analytical lens through which the nature of interplay between various actors in a regulatory regime can be better appreciated and the capacity of that regime as a whole can be enhanced in smart and innovative ways.

Met de slogan ‘Nieuwerwets boeren in de biologische sector’ trekt Van Hall Larenstein studenten naar de opleiding Ad Biologische Melkveehouderij. Hiermee wordt voorzien in een duidelijke vraag vanuit deze sector naar kennis op hbo-niveau. Twee docenten en een student vertellen wat de opleiding inhoudt.